SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection

Li, Xiaofang; Nakashima, Kenji; Ito, Masahiko; Matsuda, Mami; Chida, Takeshi; Sekihara, Kazumasa; Takahashi, Hirotaka; Kato, Takanobu; Sawasaki, Tatsuya; Suzuki, Tetsuro

doi:10.1016/j.antiviral.2023.105756

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each peptide was added during cell-free HBV Cp synthesis using wheat germ lysates and capsid assembly; HBV capsids were electrophoresed on native agarose gel and HBV capsids were detected by Western blotting (Figure 2A "Native capsid assay"). 23 Of the 72 peptides tested, peptides 19Ac and 20Ac significantly inhibited HBV-capsid formation (Figure 2B).…”

Section: Resultsmentioning

confidence: 92%

Identification of Peptide-Based Hepatitis B Virus Capsid Inhibitors Based on the Viral Core Protein

Kawahara,

Fujimoto,

Takeo

et al. 2024

Preprint

View full text Add to dashboard Cite

In this study, we have identified two novel peptides, 19Ac (comprising residues 91-105) and 20Ac (encompassing residues 96-110), from a systematically designed peptide library based on the Hepatitis B virus (HBV) core protein, that inhibit the assembly of HBV capsid. Peptide 20Ac exhibited about twofold the inhibitory potency of 19Ac and proved effective against both standard and morphothiadin (GLS4)-resistant HBV strains. Molecular dynamics simulations revealed that despite their overlapping sequence, 19Ac and 20Ac bonded to different regions of the core protein, thereby inhibiting capsid assembly through distinct mechanisms. These peptides could serve as valuable seed compounds for the further development of HBV capsid inhibitors, including GLS4-resistant strains.

show abstract

Section: Resultsmentioning

confidence: 92%